Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

With US Respiratory Pipeline Unlocked, Cipla Wants Lung Leadership

Also Sets Out Ambitions For China And Brazil

Executive Summary

Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.

You may also be interested in...



Hikma Launches Long-Awaited US Advair Rival

Hikma has gained FDA approval for and launched its long-in-development generic version of Advair Diskus. The milestone puts it in direct competition with Viatris’ Wixela Inhub version that was launched almost two years ago, in three presentations compared to Hikma’s two.

'Endemic' Coronavirus: Cipla Defines Sustainability Of Gains

The potentially endemic nature of the coronavirus could buoy gains for Cipla’s COVID-19 portfolio, which now includes an antibody detection kit. The Indian firm’s albuterol generic has also chipped away at market share in the US.

'Endemic' Coronavirus: Cipla Defines Sustainability Of Gains

The potentially endemic nature of the coronavirus could buoy gains for Cipla’s COVID-19 portfolio, which now includes an antibody detection kit. The Indian firm’s albuterol generic has also chipped away at market share in the US.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132098

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel